Cargando…
In situ Generated (212)Pb-PSMA Ligand in a (224)Ra-Solution for Dual Targeting of Prostate Cancer Sclerotic Stroma and PSMA-Positive Cells
Background: New treatments combating bone and extraskeletal metastases are needed for patients with metastatic castration-resistant prostate cancer. The majority of metastases overexpress prostate-specific membrane antigen (PSMA), making it an ideal candidate for targeted radionuclide therapy. Objec...
Autores principales: | Stenberg, Vilde Y., Juzeniene, Asta, Bruland, Øyvind S., Larsen, Roy H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bentham Science Publishers
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7527546/ https://www.ncbi.nlm.nih.gov/pubmed/32389119 http://dx.doi.org/10.2174/1874471013666200511000532 |
Ejemplares similares
-
Dual targeting with (224)Ra/(212)Pb-conjugates for targeted alpha therapy of disseminated cancers: A conceptual approach
por: Juzeniene, Asta, et al.
Publicado: (2023) -
Evaluation of the PSMA-Binding Ligand (212)Pb-NG001 in Multicellular Tumour Spheroid and Mouse Models of Prostate Cancer
por: Stenberg, Vilde Yuli, et al.
Publicado: (2021) -
Factors Influencing the Therapeutic Efficacy of the PSMA Targeting Radioligand (212)Pb-NG001
por: Stenberg, Vilde Yuli, et al.
Publicado: (2022) -
Targeted alpha therapy with the (224)Ra/(212)Pb-TCMC-TP-3 dual alpha solution in a multicellular tumor spheroid model of osteosarcoma
por: Tornes, Anna Julie Kjøl, et al.
Publicado: (2022) -
Preclinical and Clinical Status of PSMA-Targeted Alpha Therapy for Metastatic Castration-Resistant Prostate Cancer
por: Juzeniene, Asta, et al.
Publicado: (2021)